Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 5/20 | 0.54 |
| ▸ | PPARA | Q07869 | 5/20 | 0.54 |
| ▸ | CMA1 | P23946 | 2/20 | 0.49 |
| ▸ | CTSG | P08311 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | CFTR | P13569 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171102 | 0.90 | ALDH1A1 (0.51) | PPARDPPARACMA1CTSGKMT2A | |
| SCHEMBL132752 | 0.90 | KMT2A (0.51) | PPARDPPARACMA1CTSGKMT2A | |
| SCHEMBL172529 | 0.87 | ALDH1A1 (0.61) | CMA1CTSGKMT2AALDH1A1HPGD | |
| SCHEMBL134036 | 0.86 | MRGPRX4 (0.48) | PPARDPPARACMA1CTSGKMT2A | |
| SCHEMBL171096 | 0.86 | CMA1 (0.52) | CMA1CTSGKMT2AALDH1A1HPGD | |
| SCHEMBL172775 | 0.85 | ALDH1A1 (0.60) | CMA1CTSGKMT2AALDH1A1HPGD | |
| SCHEMBL131981 | 0.85 | CMA1 (0.51) | CMA1CTSGKMT2AALDH1A1HPGD | |
| SCHEMBL172461 | 0.85 | KMT2A (0.53) | CMA1CTSGKMT2AALDH1A1HPGD | |
| SCHEMBL172580 | 0.85 | CMA1 (0.54) | CMA1CTSGKMT2AALDH1A1HPGD | |
| SCHEMBL133701 | 0.85 | KMT2A (0.53) | CMA1CTSGKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334313-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2011-06-02 | — | — | US | disclosed |
| US-7902241-B2 | 3-[3-(4-ISOPROPYLPHENYL)-2,5-DIOXO-IMIDAZOLIDIN-1-YL]- or 2-OXO-2,3-DIHYDROIMIDAZOL-1-YL]BENZOIC ACID; modulating premature translation termination and nonsense-mediated mRNA decay; gene therapy; cystic fibrosis or Duchenne muscular dystrophy; cancer, autoimmune disease, blood disease, diabetes | PTC THERAPEUTICS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20080275233-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. | 2008-11-06 | — | — | US | disclosed |
| US-7405233-B2 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167065-A1 | Ureido substituted benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, VHL, URB2 | PPARD 1092/4885PPARA 910/4885CMA1 3088/4885 |
| US-20110130391-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | PPARD 1092/4885PPARA 910/4885CMA1 3088/4885 |
| US-20080275233-A1 | UREIDO SUBSTITUTED BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | UPF1, VHL, URB2 | PPARD 1092/4885PPARA 910/4885CMA1 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.